m-methoxytrityl chloride | 109938-55-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: m-methoxytrityl chloride
• 英文别名: mono-m-methoxytrityl chloride；3-(α-chloro-benzhydryl)-anisole；3-(α-Chlor-benzhydryl)-anisol；Methyl-[3-(α-chlor-benzhydryl)-phenyl]-aether；Methyl-[3-(chlor-diphenyl-methyl)-phenyl]-aether；3-Methoxy-1-(chlor-diphenyl-methyl)-benzol；Diphenyl-(3-methoxy-phenyl)-methylchlorid；3-(Chlor-diphenyl-methyl)-anisol；1-[Chloro(diphenyl)methyl]-3-methoxybenzene
• CAS: 109938-55-8
• 化学式: C₂₀H₁₇ClO
• 分子量: 308.807
• InChiKey: JKHFLVFZLJDEHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  m-methoxytrityl chloride 在 银 、 苯 作用下， 生成 3-Methoxy-trityl
  参考文献：
  名称：

  The Dissociation of Hexaarylethanes.¹ XV. Methoxyl Substituents

  摘要：

  DOI：

  10.1021/ja01231a032
• 作为产物：
  描述：

  间溴苯甲醚 在 正丁基锂 、 乙酰氯 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.5h， 生成 m-methoxytrityl chloride
  参考文献：
  名称：

  Synthesis of Bridged Molecular Gyroscopes with Closed Topologies: Triple One-Pot Macrocyclization

  摘要：

  We describe the synthesis and characterization of six bridged molecular gyroscopes with m-alkoxy-substituted trityl stators and dialkynylphenylene rotators. All of the bridged molecular gyroscopes were synthesized convergently to form the phenolic stator-rotator framework, while the alkyl and benzophenone bridges were installed in one step by relatively efficient one-pot reactions to form macrocyclic diether or diester linkages. The isolated yield per bond-forming reaction varied from ca. 42% to 80%, with one exception where macrocyclization failed to produce the desired product. The molecular structure and crystal packing of each of the bridged molecular gyroscopes were determined via single crystal X-ray diffraction. Like most molecular gyroscopes with open topologies previously studied, the singly bridged structures pack by interdigitating one trityl stator in one molecule next to the rotator of an adjacent molecule in the lattice. In contrast, the triply bridged molecular gyroscopes were found to pack in lamellar sheets that prevent the rotator-stator interdigitation of adjacent molecules. However, solvent molecules and conformationally flexible bridges tend to fill in the packing volume by collapsing next to the rotator or by extending one of their bridges into the cavity of a neighboring molecule.

  DOI：

  10.1021/jo201513y

文献信息

• CONJUGATES COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST, A LINKER AND HYALURONIC ACID
  申请人：SANOFI

  公开号：US20180154005A1

  公开（公告）日：2018-06-07

  The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L 1 -L 2 -L-Y—R 20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (la), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.

  本发明涉及一种共轭物或其药用可接受盐，包括GLP-1/胰高血糖素受体激动剂、连接剂和携带-L1-L2-L-Y—R20基团的透明质酸水凝胶，其中Y代表GLP-1/胰高血糖素受体激动剂基团；而-L是连接剂基团—按照公式（la），其中虚线表示通过形成酰胺键与GLP-1/胰高血糖素受体激动剂基团的氨基之一连接。该发明还涉及包含所述共轭物的药物组合物，以及它们作为治疗或预防可通过GLP-1/胰高血糖素受体激动剂治疗的疾病或紊乱的药物的用途。
• Linear Relationship between ¹³ C NMR Chemical Shifts and the Bending of sp‐Carbon Chains
  作者：Mathis Kreuzahler、Abdulselam Adam、Gebhard Haberhauer

  DOI：10.1002/chem.201902617

  日期：2019.10

  of the nonlinearity in solution. Herein, we show that the 13 C NMR spectroscopy represents an appropriate tool for this as we found an almost perfect linear relationship between the bending of the alkyne chain and the change of the chemical shift of the outer acetylenic carbon atoms. By using molecular bows in which the alkyne chain can be bent by switching the azobenzene unit, this correlation can be

  Polyynes在能量影响和Polyyne链的弯曲之间显示出严格的线性关系。弯曲炔链所需的能量随着乙炔单元数目的增加而降低。违反红外和拉曼光谱之间的互斥原理，可以在解决方案中实现多炔的线性度偏差。但是，仍然不可能测量溶液中的非线性程度。本文中，我们显示13 C NMR光谱为此提供了一种合适的工具，因为我们发现炔烃链的弯曲与外部炔碳原子化学位移的变化之间存在几乎完美的线性关系。通过使用其中可以通过切换偶氮苯单元来弯曲炔烃链的分子弓，可以通过实验证明这种相关性。将来，这种相关性应该能够确定弯曲的程度和聚炔的应变能。因此，聚炔可以用作测量进一步的分子力的探针。
• Influence of Some Novel N-Substituted Azoles and Pyridines on Rat Hepatic CYP3A Activity
  作者：James T. Slama、Julie L. Hancock、Taikyun Rho、Lidia Sambucetti、Kenneth A. Bachmann

  DOI：10.1016/s0006-2952(98)00096-3

  日期：1998.6

  A series of N-substituted heteroaromatic compounds structurally related to clotrimazole was synthesized, and the effects of these compounds on ethosuximide clearance in rats were determined as a measure of their abilities to induce cytochrome P4503A (CYP3A) activity. Ethosuximide clearance and in vitro erythromycin N-demethylase activity were shown to correlate. In this series, imidazole or other related

  合成了一系列与克霉唑相关的N-取代杂芳族化合物，并确定了这些化合物对大鼠乙硫酰亚胺清除率的影响，以此来衡量它们诱导细胞色素P4503A（CYP3A）活性的能力。乙草胺清除率和体外红霉素N-脱甲基酶活性显示出相关性。在该系列中，咪唑或其他相关的杂芳族“头基”与三苯基甲烷或其他苯基甲烷衍生物连接。在该系列中，发现1-三苯基甲烷取代的咪唑引起CYP3A活性的最大增加，而在三苯基甲基取代的咪唑中，通过间位或Cl-中的F-或Cl-取代获得最高的活性。苯环之一的对位。二苯甲基取代的吡啶实际上没有活性。引起CYP3A活性最大增加的化合物（即1-[（（3-氟苯基）二苯基甲基]咪唑，1-[（（4-氟苯基）二苯基甲基]咪唑和1- [三-（4-氟苯基）甲基]咪唑）产生的乙氧基间苯二酚O-脱烷基酶（EROD）活性（即CYP1A）几乎没有增加，而苄基咪唑仅引起CYP3A活性少量增加，而CYP1A活性几乎增加了9倍。
• Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid
  申请人：SANOFI

  公开号：US10792367B2

  公开（公告）日：2020-10-06

  The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.

  本发明涉及一种共轭物或其药学上可接受的盐，该共轭物或其药学上可接受的盐包含一种 GLP-1/Glucagon 受体激动剂、一种连接基团和一种带有-L1-L2-L-Y-R20 基团的透明质酸水凝胶，其中 Y 代表一种 GLP-1/Glucagon 受体激动剂分子；-L 是一种连接基团--按式 (Ia)、 其中虚线表示通过形成酰胺键连接到 GLP-1/Glucagon 受体激动剂分子的一个氨基上。本发明还涉及包含这些共轭物的药物组合物，以及它们作为治疗或预防可由 GLP-1/Glucagon 受体激动剂治疗的疾病或紊乱的药物的用途。
• Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
  申请人：SANOFI

  公开号：US10806797B2

  公开（公告）日：2020-10-20

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.

  本发明涉及一种原药或其药学上可接受的盐，其包含GLP-1/胰高血糖素激动剂连接体共轭物Z-L1-L2-L-Y-R20，其中Y代表GLP-1/胰高血糖素激动剂分子；和-L是连接体分子-式(Ia)，其中虚线表示通过形成酰胺键连接到GLP-1/胰高血糖素激动剂分子的氨基之一。本发明还涉及包含上述原药的药物组合物，以及它们作为药物治疗或预防可由 GLP-1/Glucagon 激动剂治疗的疾病或紊乱的用途。